Pfizer Inc. (NYSE:PFE) Stake Trimmed by Peddock Capital Advisors LLC

Peddock Capital Advisors LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 22.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 37,888 shares of the biopharmaceutical company’s stock after selling 10,856 shares during the period. Peddock Capital Advisors LLC’s holdings in Pfizer were worth $1,091,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Beacon Financial Advisory LLC lifted its position in shares of Pfizer by 3.4% in the third quarter. Beacon Financial Advisory LLC now owns 29,245 shares of the biopharmaceutical company’s stock worth $970,000 after purchasing an additional 956 shares in the last quarter. Canal Capital Management LLC boosted its holdings in Pfizer by 2.4% in the third quarter. Canal Capital Management LLC now owns 21,326 shares of the biopharmaceutical company’s stock worth $707,000 after purchasing an additional 506 shares in the last quarter. Concord Wealth Partners increased its position in Pfizer by 51.9% during the third quarter. Concord Wealth Partners now owns 15,843 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 5,412 shares during the last quarter. JB Capital LLC lifted its position in shares of Pfizer by 22.0% in the third quarter. JB Capital LLC now owns 154,540 shares of the biopharmaceutical company’s stock worth $5,126,000 after buying an additional 27,868 shares during the last quarter. Finally, ETF Store Inc. boosted its stake in shares of Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $36.00.

Pfizer Price Performance

Pfizer stock traded up $0.47 on Wednesday, reaching $28.24. The company’s stock had a trading volume of 24,330,357 shares, compared to its average volume of 43,361,477. The business’s fifty day moving average price is $26.92 and its 200 day moving average price is $28.12. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market cap of $159.91 billion, a price-to-earnings ratio of -466.42, a PEG ratio of 1.17 and a beta of 0.63. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue was down 19.5% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.95%. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.